2019年 5月 6日
EMERGO BY UL SUMMARY OF KEY POINTS:
Health Canada has published new guidance for manufacturers of higher-risk 3D-printed medical devices regarding what to include in their Medical Device License (MDL) applications and commercialize in the country.
The guidance covers design and manufacturing processes, material controls, testing and labeling recommendations for companies with Class III and Class IV implantable devices produced via additive manufacturing. Health Canada explicitly excludes standalone software, custom-made medical devices and bio-printed products from the scope of the guidance.
Health Canada notes that its recommendations for 3D-printed medical device regulatory requirements track closely to those issued by the International Medical Device Regulators Forum (IMDRF) and US FDA.
Beyond general requirements Health Canada has established for all implantable Class III and IV MDL submissions, the regulator has now also specified additional submission data expected from 3D-printed device manufacturers.
Below, we discuss Health Canada MDL application data specifically required for 3D-printed devices:
The device description of the MDL application should cover not only the finished device but also starting material information, including references to any pertinent material standards; starting material chemical composition; and identification of any additives or processing agents added to the starting material.
MDL submissions for devices that have been patient-matched or custom-made instead of produced according to predetermined specifications should include the following information in their device description sections:
Health Canada states that evaluation of these and related parameters will be used to determine suitability of a 3D-printed device’s starting material.
Additional information required under the “device description” category include design philosophy (i.e., why the MDL applicant chose additive rather than more conventional manufacturing methods for the device); any data regarding proposed device changes or modifications if the manufacturer is submitting a license amendment application; and marketing history as well as regulatory status either for the device itself or for a relevant and comparable device already approved by Health Canada.
Safety and effectiveness claims in MDL submissions for 3D-printed devices should be supported by materials including:
Proper device design and identification labeling must also take into account patient privacy and confidentiality regarding patient-matched devices, according to the guidance.
Health Canada suggests patient name, anatomical location for implantation, and/or final design iteration or version of device production method as potentially suitable labeling items.